Kathleen Judge, MD
Dermatology · Orlando, FLNPI 1225146202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $575 of the $939 with a category attached, or 61.2%. 11 manufacturers reported payments, led by Johnson & Johnson at 27.5% of the total. That places this record below the midpoint for dermatology clinicians in FL, where the typical reported total is $2,563.
Across 37 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$258
- AbbVie$176
- Galderma Laboratories, L.p.$153
- E.r. Squibb & Sons, L.L.C.$95
- LEO Pharma Inc.$75
- Sun Pharmaceutical Industries Inc.$72
- plus $110 from 5 others
Across 11 payments — averaging $508.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$6K
What the payments were for
- Food & beverage$57561%
- Education$36439%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $258 |
| AbbVie(2 entities) | 9 | $176 |
| Galderma Laboratories, L.p. | 8 | $153 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| LEO Pharma Inc. | 5 | $75 |
| Sun Pharmaceutical Industries Inc. | 1 | $72 |
| Dermavant Sciences, Inc. | 2 | $32 |
| Sanofi | 1 | $29 |
| Incyte Corporation | 1 | $19 |
| Amgen | 1 | $18 |
| Merck | 1 | $13 |
How this compares
$939 in reported general payments places this provider in the 30th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 370 | $2,754 |
| Clobetasol Propionate | 44 | $2,108 |
| Metronidazole | 24 | $1,811 |
| Ketoconazole | 56 | $935 |
| Fluorouracil | 18 | $862 |
| Triamcinolone Acetonide | 112 | $794 |
| Doxycycline Hyclate | 47 | $576 |
| Clindamycin Phosphate | 11 | $531 |
| Fluocinonide | 12 | $371 |
| Mometasone Furoate | 21 | $293 |
| ValacyclovirValacyclovir Hcl | 12 | $256 |
| Nystatin | 12 | $254 |
| Hydroxyzine Hcl | 16 | $111 |
| Hydrocortisone | 16 | $90 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Orlando
- Debra GraymanOrlando$166K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.